European Heart Journal Advance Access originally published online on April 12, 2005
European Heart Journal 2005 26(16):1653-1659; doi:10.1093/eurheartj/ehi251
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey
1Department of Cardiology, Pitie-Salpetriere Hospital, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France
2Bristol-Myers-Squibb Outcomes Research, Brussels, Belgium
3Department of Cardiology, Hospital Clinico Universitario de Santiago de Compostela, Spain
4Department of Cardiology, University Hospital Groningen, Groningen, The Netherlands
5Department of Medicine III, University of Cologne, Germany
6Division of Cardiology, IRCCS Policlinico San Matteo Hospital, Pavia, Italy
7National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK
8CLP Santé, Paris, France
Received 20 August 2004; revised 1 March 2005; accepted 3 March 2005; online publish-ahead-of-print 12 April 2005.
* Corresponding author. Tel: +33 1 4216 3003; fax: +33 1 4216 3020. E-mail address: michel.komajda{at}psl.ap-hop-paris.fr
Aims The impact on outcome of the implementation of European guidelines for the treatment of chronic heart failure (CHF) has not been evaluated. We investigated the consequences of adherence to care by cardiologists on the rate of CHF and cardiovascular (CV) hospitalizations and time to CV hospitalization.
Methods and results We constructed class adherence indicators for angiotensin-converting enzyme (ACE)-inhibitors, beta-blockers, spironolactone, diuretics, and cardiac glycosides and GAIs (GAI3 adherence to first three classes of heart failure medication, GAI5 adherence to five classes). In the study, 1410 evaluable patients (mean age 69, 69% males, New York Heart Association (NYHA) II: 64%, III: 34%, IV: 2%) were enrolled and followed up for 6 months by 150 randomly selected cardiologists/cardiology departments from six European countries (France, Germany, Italy, The Netherlands, Spain, and UK).
Overall, adherence to treatment guidelines was 60 (GAI3) and 63% (GAI5) and was better for ACE-I (88%) or diuretics (82%) than for cardiac glycosides (52%), beta-blockers (58%), and spironolactone (36%). In the three tertiles of the population defined by a decreasing mean adherence score value, CHF and CV hospitalization rates were, respectively, 6.7, 9.7, and 14.7% and 11.2, 15.9, and 20.6% (P<0.002 and P<0.001, respectively). Global adherence indicator GAI3 was an independent predictor of time to CV hospitalization in a multi-variable model together with NYHA Class, history of CHF hospitalization, ischaemic aetiology, diabetes mellitus, and hypertension.
Conclusion We demonstrate that adherence of physicians to treatment guidelines is a strong predictor of fewer CV hospitalizations in actual practice. There is a need to develop further quality improvement programmes in this condition.
Key Words: Guidelines • Chronic heart failure • Care indicators • Outcome
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T Jaarsma Secondary prevention of coronary heart disease and heart failure in primary care Heart, September 1, 2008; 94(9): 1211 - 1211. [Full Text] [PDF]
|
|
|
|
|
|
R Chung, R Sutton, and M Y Henein Beyond dyssynchrony in cardiac resynchronisation therapy Heart, August 1, 2008; 94(8): 991 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Remme, J. J.V. McMurray, F.D. R. Hobbs, A. Cohen-Solal, J. Lopez-Sendon, A. Boccanelli, F. Zannad, B. Rauch, K. Keukelaar, C. Macarie, et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians Eur. Heart J., July 2, 2008; 29(14): 1739 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Jaarsma, M. H. L. van der Wal, I. Lesman-Leegte, M.-L. Luttik, J. Hogenhuis, N. J. Veeger, R. Sanderman, A. W. Hoes, W. H. van Gilst, D. J. A. Lok, et al. Effect of Moderate or Intensive Disease Management Program on Outcome in Patients With Heart Failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Arch Intern Med, February 11, 2008; 168(3): 316 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Komajda, O. Hanon, M. Hochadel, F. Follath, K. Swedberg, A. Gitt, and J. G.F. Cleland Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I Eur. Heart J., June 1, 2007; 28(11): 1310 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Erdmann, J. A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I. K. Moules, A. M. Skene, and on behalf of the PROactive Investigators The Effect of Pioglitazone on Recurrent Myocardial Infarction in 2,445 Patients With Type 2 Diabetes and Previous Myocardial Infarction: Results From the PROactive (PROactive 05) Study J. Am. Coll. Cardiol., May 1, 2007; 49(17): 1772 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Mullen, E. H. Bradley, I. A. Mansi, D. N. Schumacher, B. W. Cooper, P. Lindenauer, D. Remus, and D. Bratzler Public Reporting and Pay for Performance N. Engl. J. Med., April 26, 2007; 356(17): 1782 - 1784. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Willenheimer and P. Lechat New concepts in managing patients with chronic heart failure: the evolving importance of beta-blockade Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C3 - C4. [Full Text] [PDF]
|
|
|
|
|
|
F. Follath Beta-blockade today: the gap between evidence and practice Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C28 - C34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ponikowski Rationale and design of CIBIS III Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C35 - C42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Willenheimer How to begin treatment in chronic heart failure? Results of CIBIS III Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C43 - C50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Stromer and M. Camerer Adherence to guidelines is a predictor of outcome in chronic heart failure: the Mahler survey Eur. Heart J., January 2, 2006; 27(2): 247 - 248. [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2125 - 2133. [Full Text] [PDF]
|
|
|
|
|
|
S. Silber and on behalf of the ESC-PCI Guidelines Task Force ESC guidelines for percutaneous coronary interventions: reply Eur. Heart J., November 2, 2005; 26(22): 2476 - 2477. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Willenheimer, D. J. van Veldhuisen, B. Silke, E. Erdmann, F. Follath, H. Krum, P. Ponikowski, A. Skene, L. van de Ven, P. Verkenne, et al. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III Circulation, October 18, 2005; 112(16): 2426 - 2435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Willenheimer Implications of CIBIS III: A Commentary Journal of Renin-Angiotensin-Aldosterone System, September 1, 2005; 6(3): 115 - 120. [Abstract] [PDF]
|
|
|
|
|
|
K. Swedberg Review: Effective Implementation of the New ESC Guidelines for the Management of Chronic Heart Failure in Routine Clinical Practice Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2_suppl): S6 - S10. [Abstract] [PDF]
|
|
|
|
|
|
A. Pietro Maggioni Symptomatic despite Multiple Drug Therapy: Where do you Turn Next? Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2_suppl): S13 - S14. [Abstract] [PDF]
|
|